Nabi Discontinues StaphVax After Confirmatory Phase III Trial Fails
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Nabi Biopharmaceuticals is halting development of its Staphylococcus aureus vaccine StaphVax after the product's failure to show efficacy in a 3,600-patient confirmatory trial